课题基金 / 基金详情

Development of Selective HDAC6 Small Molecule Inhibitors for the Treatment of Brain Cancers

Development of Selective HDAC6 Small Molecule Inhibitors for the Treatment of Brain Cancers
开发用于治疗脑癌的选择性 HDAC6 小分子抑制剂
批准号：
470153
负责人：
Gunning Patrick T
金额：
$49.32万
依托单位：
University of Toronto
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2022
资助国家：
加拿大
项目状态：
未结题
起止时间：
2022-09-01 至 2026-09-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=470153&lang=en
关键词：
Brain Cancer Histone Deacetylase Medicinal Chemistry Selective Small Molecule Inhibitor Xenograft Mouse Model

项目摘要

项目成果

Gunning Patrick T的其他基金

相似基金

相关文献

中文摘要
翻译
脑癌是最具侵袭性的肿瘤之一，通过药物治疗尤其具有挑战性。这部分是因为大脑受到血脑屏障的保护，血脑屏障可以保护大脑免受各种外来物质的影响，
英文摘要
Brain cancers represent one of the most aggressive tumors that are especially challenging to treat through drugs. This is partly because the brain is protected by a blood-brain-barrier, which shields the brain from a variety of foreign substances, includi
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Canada Research Chair - Tier 2 - CIHR Funded
  • 批准号：
    384907
  • 项目类别：
  • 资助金额：
    $36.43万
  • 财政年份：
    2017
  • 负责人：
    Gunning Patrick T
  • 依托单位：
    University of Toronto
Extending life in refractory medulloblastoma patients with cancer stem cell killing small molecules
Small molecules targeting aberrant STAT3 activity: killing breast tumour cells and inducing an anti-tumour immune response.
Developing STAT5 protein inhibitors for treatment of Leukemia
海外基金